Fosamax and Osteonecrosis of the Jaw: Causation and Risk – What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From Clinical Trial Data to Individual Risk Assessment

This domain has a legacy of curating and analyzing publicly available structured clinical trial data from sources such as ClinicalTrials.gov, EUCTR, PubMed, and FDA databases. Our established practice involves extracting and synthesizing information on drug safety, adverse events, and comparative efficacy across a broad spectrum of therapeutic areas. This foundation provides a rigorous, data-driven framework for evaluating pharmaceutical risk profiles. From this general health and science information context, we now pivot to a specific occupational exposure concern: the documented link between bisphosphonate use, notably Fosamax (alendronate), and the development of osteonecrosis of the jaw (ONJ). While clinical trials provide aggregate safety data, the occupational context demands a more granular assessment of exposure duration, dosage, and patient-specific factors that may elevate risk. This shift moves from broad epidemiological patterns to the practical implications for healthcare professionals and patients managing long-term therapy. The concern is not merely statistical but operational: how to identify, monitor, and mitigate this rare but serious adverse event in real-world clinical settings.

Understanding Fosamax and Its Mechanism of Action

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, necrotic bone in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis is typically based on clinical examination and imaging, with a focus on identifying exposed bone in the oral cavity that persists for more than eight weeks. The condition can lead to significant morbidity, including chronic pain, infection, and difficulty eating.

Mechanistic Pathways and Risk Factors for ONJ

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current research suggests that bisphosphonates suppress bone turnover by inhibiting osteoclast activity, which may impair the jawbone's ability to remodel and repair microdamage. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research indicates that the jawbone has unique structural and cellular properties that may make it particularly susceptible to the effects of bisphosphonates, such as reduced vascularity and altered immune responses. Additionally, known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Duration of Therapy

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions.' It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the optimal duration of use for osteoporosis treatment, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This lack of clear duration guidance may leave some patients exposed to prolonged bisphosphonate therapy without adequate monitoring for ONJ risk.

Causation Evidence: Temporal Relationship and Rechallenge Data

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as the condition improves upon discontinuation and recurs upon re-exposure. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that the background incidence of ONJ in the general population is low, but the drug may increase risk in susceptible individuals.

Risk Over Time and Clinical Management

The timeline between exposure and documented harm can vary widely. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This indicates that the risk of ONJ increases with longer duration of Fosamax use, but the absolute risk remains small. For patients who develop ONJ, the condition can be challenging to manage, often requiring dental surgery, antibiotics, and discontinuation of the bisphosphonate. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is an effective treatment for osteoporosis, but it carries a risk of ONJ, particularly with prolonged use. The prescribing information includes warnings about this risk, but the optimal duration of therapy remains undefined. Patients should be informed about the signs and symptoms of ONJ and advised to maintain good oral hygiene and avoid invasive dental procedures while on bisphosphonate therapy. For those who develop ONJ, discontinuation of Fosamax may lead to symptom relief, and the risk diminishes after stopping the drug. Healthcare providers should weigh the benefits of fracture prevention against the low but real risk of ONJ when prescribing Fosamax.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), a condition where the jawbone becomes exposed and necrotic. The risk is higher with prolonged use, and the prescribing information includes warnings about this adverse effect. Studies show that the risk increases with duration of therapy, but absolute risk remains low (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

The exact mechanism is not fully understood, but bisphosphonates like Fosamax suppress bone turnover by inhibiting osteoclast activity, which may impair the jawbone's ability to repair microdamage. The jawbone has unique properties that may make it more susceptible (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and pre-existing dental disease. The risk also increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What does the Fosamax label say about ONJ?

The label includes a warning about ONJ under 'Warnings and Precautions,' noting that it has been reported and is generally associated with tooth extraction or local infection. It advises that discontinuation may reduce risk for patients needing invasive dental procedures, but does not specify optimal duration of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.